NO870237L - Fremgangsmaate og system for liposominhalering. - Google Patents

Fremgangsmaate og system for liposominhalering. Download PDF

Info

Publication number: NO870237L
Authority: NO; Norway
Prior art keywords: drug; liposomes; liposome; suspension; encapsulated
Prior art date: 1985-05-22

Application number

NO870237A

Other languages

English (en)

Norwegian (no)

Inventor

Paul J Mihalko

Robert M Abra

Original Assignee

Liposome Technology Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1985-05-22

Filing date

1987-01-20

Publication date

1987-01-20

1987-01-20 Application filed by Liposome Technology Inc filed Critical Liposome Technology Inc

1987-01-20 Publication of NO870237L publication Critical patent/NO870237L/no

Links

238000000034 method Methods 0.000 title claims abstract description 49
229940079593 drug Drugs 0.000 claims abstract description 280
239000003814 drug Substances 0.000 claims abstract description 280
239000002502 liposome Substances 0.000 claims abstract description 269
239000000725 suspension Substances 0.000 claims abstract description 60
239000002245 particle Substances 0.000 claims abstract description 43
239000003380 propellant Substances 0.000 claims abstract description 28
239000000203 mixture Substances 0.000 claims description 52
230000000694 effects Effects 0.000 claims description 45
210000003437 trachea Anatomy 0.000 claims description 31
238000012387 aerosolization Methods 0.000 claims description 24
230000009885 systemic effect Effects 0.000 claims description 22
150000003904 phospholipids Chemical class 0.000 claims description 18
NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 claims description 16
238000002156 mixing Methods 0.000 claims description 16
238000000338 in vitro Methods 0.000 claims description 15
KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims description 13
-1 flunoisolide Chemical compound 0.000 claims description 10
239000002609 medium Substances 0.000 claims description 10
239000012736 aqueous medium Substances 0.000 claims description 7
239000007900 aqueous suspension Substances 0.000 claims description 7
SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 claims description 5
239000000006 Nitroglycerin Substances 0.000 claims description 5
229960003711 glyceryl trinitrate Drugs 0.000 claims description 5
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 4
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 4
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 4
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 4
102000003978 Tissue Plasminogen Activator Human genes 0.000 claims description 4
108090000373 Tissue Plasminogen Activator Proteins 0.000 claims description 4
210000004369 blood Anatomy 0.000 claims description 4
239000008280 blood Substances 0.000 claims description 4
239000003795 chemical substances by application Substances 0.000 claims description 4
238000013267 controlled drug release Methods 0.000 claims description 4
201000010099 disease Diseases 0.000 claims description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
150000002148 esters Chemical class 0.000 claims description 4
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 4
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims description 4
229960000187 tissue plasminogen activator Drugs 0.000 claims description 4
229940124158 Protease/peptidase inhibitor Drugs 0.000 claims description 3
APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims description 3
239000008346 aqueous phase Substances 0.000 claims description 3
229940092705 beclomethasone Drugs 0.000 claims description 3
NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 claims description 3
229940124630 bronchodilator Drugs 0.000 claims description 3
229960000265 cromoglicic acid Drugs 0.000 claims description 3
229960003957 dexamethasone Drugs 0.000 claims description 3
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 3
229940094443 oxytocics prostaglandins Drugs 0.000 claims description 3
239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 3
150000003180 prostaglandins Chemical class 0.000 claims description 3
XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 claims description 2
FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 claims description 2
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 2
SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 claims description 2
WTRRIQCGCGCMQA-CBZIJGRNSA-N 3-Hydroxyestra-1,3,5(10),6-tetraen-17-one Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3C=CC2=C1 WTRRIQCGCGCMQA-CBZIJGRNSA-N 0.000 claims description 2
APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 claims description 2
102000000412 Annexin Human genes 0.000 claims description 2
108050008874 Annexin Proteins 0.000 claims description 2
101710081722 Antitrypsin Proteins 0.000 claims description 2
102000002723 Atrial Natriuretic Factor Human genes 0.000 claims description 2
101800001288 Atrial natriuretic factor Proteins 0.000 claims description 2
108010006654 Bleomycin Proteins 0.000 claims description 2
102000055006 Calcitonin Human genes 0.000 claims description 2
108060001064 Calcitonin Proteins 0.000 claims description 2
MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 claims description 2
MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 claims description 2
102400001368 Epidermal growth factor Human genes 0.000 claims description 2
101800003838 Epidermal growth factor Proteins 0.000 claims description 2
102000001690 Factor VIII Human genes 0.000 claims description 2
108010054218 Factor VIII Proteins 0.000 claims description 2
229930182566 Gentamicin Natural products 0.000 claims description 2
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims description 2
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 2
108090001061 Insulin Proteins 0.000 claims description 2
102000004877 Insulin Human genes 0.000 claims description 2
108010050904 Interferons Proteins 0.000 claims description 2
102000014150 Interferons Human genes 0.000 claims description 2
108010002350 Interleukin-2 Proteins 0.000 claims description 2
102000000588 Interleukin-2 Human genes 0.000 claims description 2
PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 2
102000000528 Pulmonary Surfactant-Associated Proteins Human genes 0.000 claims description 2
108010041520 Pulmonary Surfactant-Associated Proteins Proteins 0.000 claims description 2
102000019197 Superoxide Dismutase Human genes 0.000 claims description 2
108010012715 Superoxide dismutase Proteins 0.000 claims description 2
108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 2
GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 claims description 2
108010004977 Vasopressins Proteins 0.000 claims description 2
102000002852 Vasopressins Human genes 0.000 claims description 2
229930003427 Vitamin E Natural products 0.000 claims description 2
MKFFGUZYVNDHIH-UHFFFAOYSA-N [2-(3,5-dihydroxyphenyl)-2-hydroxyethyl]-propan-2-ylazanium;sulfate Chemical compound OS(O)(=O)=O.CC(C)NCC(O)C1=CC(O)=CC(O)=C1.CC(C)NCC(O)C1=CC(O)=CC(O)=C1 MKFFGUZYVNDHIH-UHFFFAOYSA-N 0.000 claims description 2
229960004308 acetylcysteine Drugs 0.000 claims description 2
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims description 2
229960003942 amphotericin b Drugs 0.000 claims description 2
230000001475 anti-trypsic effect Effects 0.000 claims description 2
KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 claims description 2
SNHRLVCMMWUAJD-SUYDQAKGSA-N betamethasone valerate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O SNHRLVCMMWUAJD-SUYDQAKGSA-N 0.000 claims description 2
229960004311 betamethasone valerate Drugs 0.000 claims description 2
229960001561 bleomycin Drugs 0.000 claims description 2
OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 2
229960004015 calcitonin Drugs 0.000 claims description 2
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 2
229950008486 carperitide Drugs 0.000 claims description 2
NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 claims description 2
229960004544 cortisone Drugs 0.000 claims description 2
229960004679 doxorubicin Drugs 0.000 claims description 2
229940116977 epidermal growth factor Drugs 0.000 claims description 2
229960005309 estradiol Drugs 0.000 claims description 2
229930182833 estradiol Natural products 0.000 claims description 2
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 2
229960005420 etoposide Drugs 0.000 claims description 2
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 2
229960001680 ibuprofen Drugs 0.000 claims description 2
229940125396 insulin Drugs 0.000 claims description 2
229940079322 interferon Drugs 0.000 claims description 2
MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 claims description 2
229960000201 isosorbide dinitrate Drugs 0.000 claims description 2
229940042006 metaproterenol sulfate Drugs 0.000 claims description 2
XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 claims description 2
229960004448 pentamidine Drugs 0.000 claims description 2
229960003387 progesterone Drugs 0.000 claims description 2
239000000186 progesterone Substances 0.000 claims description 2
AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 claims description 2
229960002052 salbutamol Drugs 0.000 claims description 2
229960000195 terbutaline Drugs 0.000 claims description 2
229960003604 testosterone Drugs 0.000 claims description 2
229960000278 theophylline Drugs 0.000 claims description 2
239000002753 trypsin inhibitor Substances 0.000 claims description 2
102000003390 tumor necrosis factor Human genes 0.000 claims description 2
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 2
229960003726 vasopressin Drugs 0.000 claims description 2
229960001722 verapamil Drugs 0.000 claims description 2
235000019165 vitamin E Nutrition 0.000 claims description 2
239000011709 vitamin E Substances 0.000 claims description 2
229940046009 vitamin E Drugs 0.000 claims description 2
150000003839 salts Chemical class 0.000 claims 2
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 1
229930182555 Penicillin Natural products 0.000 claims 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims 1
VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 claims 1
229960002897 heparin Drugs 0.000 claims 1
229920000669 heparin Polymers 0.000 claims 1
LMOINURANNBYCM-UHFFFAOYSA-N metaproterenol Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 claims 1
229960002657 orciprenaline Drugs 0.000 claims 1
229940049954 penicillin Drugs 0.000 claims 1
239000002904 solvent Substances 0.000 abstract description 33
210000002345 respiratory system Anatomy 0.000 abstract 1
238000002360 preparation method Methods 0.000 description 81
150000002632 lipids Chemical class 0.000 description 67
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 58
235000012000 cholesterol Nutrition 0.000 description 29
239000000443 aerosol Substances 0.000 description 22
239000000463 material Substances 0.000 description 22
238000005538 encapsulation Methods 0.000 description 18
239000012528 membrane Substances 0.000 description 18
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 17
ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 16
AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 15
239000006199 nebulizer Substances 0.000 description 15
206010006482 Bronchospasm Diseases 0.000 description 13
241001465754 Metazoa Species 0.000 description 13
239000000839 emulsion Substances 0.000 description 13
230000007885 bronchoconstriction Effects 0.000 description 12
239000005720 sucrose Substances 0.000 description 12
238000011282 treatment Methods 0.000 description 12
125000002252 acyl group Chemical group 0.000 description 11
238000012377 drug delivery Methods 0.000 description 11
239000012071 phase Substances 0.000 description 11
239000006185 dispersion Substances 0.000 description 10
238000009826 distribution Methods 0.000 description 10
239000000243 solution Substances 0.000 description 10
230000008021 deposition Effects 0.000 description 9
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 8
OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 8
229960004373 acetylcholine Drugs 0.000 description 8
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 8
238000001647 drug administration Methods 0.000 description 8
238000002474 experimental method Methods 0.000 description 8
238000004519 manufacturing process Methods 0.000 description 8
239000003595 mist Substances 0.000 description 8
239000002953 phosphate buffered saline Substances 0.000 description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 7
229930006000 Sucrose Natural products 0.000 description 7
BIABMEZBCHDPBV-UHFFFAOYSA-N dipalmitoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-UHFFFAOYSA-N 0.000 description 7
230000002685 pulmonary effect Effects 0.000 description 7
230000001225 therapeutic effect Effects 0.000 description 7
NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 6
241000282472 Canis lupus familiaris Species 0.000 description 6
229930182558 Sterol Natural products 0.000 description 6
230000009471 action Effects 0.000 description 6
239000004067 bulking agent Substances 0.000 description 6
230000015556 catabolic process Effects 0.000 description 6
230000008859 change Effects 0.000 description 6
238000001125 extrusion Methods 0.000 description 6
239000007788 liquid Substances 0.000 description 6
239000004417 polycarbonate Substances 0.000 description 6
229920000515 polycarbonate Polymers 0.000 description 6
230000008569 process Effects 0.000 description 6
229920006395 saturated elastomer Polymers 0.000 description 6
150000003432 sterols Chemical class 0.000 description 6
235000003702 sterols Nutrition 0.000 description 6
DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 5
230000000875 corresponding effect Effects 0.000 description 5
238000011534 incubation Methods 0.000 description 5
210000004072 lung Anatomy 0.000 description 5
239000003550 marker Substances 0.000 description 5
150000008105 phosphatidylcholines Chemical class 0.000 description 5
AJDIZQLSFPQPEY-UHFFFAOYSA-N 1,1,2-Trichlorotrifluoroethane Chemical compound FC(F)(Cl)C(F)(Cl)Cl AJDIZQLSFPQPEY-UHFFFAOYSA-N 0.000 description 4
CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 description 4
RFCAUADVODFSLZ-UHFFFAOYSA-N 1-Chloro-1,1,2,2,2-pentafluoroethane Chemical compound FC(F)(F)C(F)(F)Cl RFCAUADVODFSLZ-UHFFFAOYSA-N 0.000 description 4
108091003079 Bovine Serum Albumin Proteins 0.000 description 4
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
239000000232 Lipid Bilayer Substances 0.000 description 4
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 4
238000010521 absorption reaction Methods 0.000 description 4
239000007864 aqueous solution Substances 0.000 description 4
230000004888 barrier function Effects 0.000 description 4
229940098773 bovine serum albumin Drugs 0.000 description 4
238000005119 centrifugation Methods 0.000 description 4
230000006378 damage Effects 0.000 description 4
229960003724 dimyristoylphosphatidylcholine Drugs 0.000 description 4
238000001704 evaporation Methods 0.000 description 4
239000010408 film Substances 0.000 description 4
239000012530 fluid Substances 0.000 description 4
230000036571 hydration Effects 0.000 description 4
238000006703 hydration reaction Methods 0.000 description 4
238000012544 monitoring process Methods 0.000 description 4
210000002381 plasma Anatomy 0.000 description 4
230000009467 reduction Effects 0.000 description 4
238000005507 spraying Methods 0.000 description 4
230000007704 transition Effects 0.000 description 4
238000000108 ultra-filtration Methods 0.000 description 4
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
102400000050 Oxytocin Human genes 0.000 description 3
101800000989 Oxytocin Proteins 0.000 description 3
XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 3
101001000212 Rattus norvegicus Decorin Proteins 0.000 description 3
238000000889 atomisation Methods 0.000 description 3
230000008901 benefit Effects 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
230000037396 body weight Effects 0.000 description 3
WLNARFZDISHUGS-MIXBDBMTSA-N cholesteryl hemisuccinate Chemical compound C1C=C2C[C@@H](OC(=O)CCC(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 WLNARFZDISHUGS-MIXBDBMTSA-N 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
230000003247 decreasing effect Effects 0.000 description 3
238000006731 degradation reaction Methods 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 3
235000019404 dichlorodifluoromethane Nutrition 0.000 description 3
FVJZSBGHRPJMMA-UHFFFAOYSA-N distearoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCCCC FVJZSBGHRPJMMA-UHFFFAOYSA-N 0.000 description 3
238000001035 drying Methods 0.000 description 3
230000008020 evaporation Effects 0.000 description 3
238000001914 filtration Methods 0.000 description 3
238000011835 investigation Methods 0.000 description 3
230000007774 longterm Effects 0.000 description 3
238000005259 measurement Methods 0.000 description 3
239000002808 molecular sieve Substances 0.000 description 3
229960001723 oxytocin Drugs 0.000 description 3
238000005192 partition Methods 0.000 description 3
239000000813 peptide hormone Substances 0.000 description 3
239000011148 porous material Substances 0.000 description 3
230000002035 prolonged effect Effects 0.000 description 3
238000000926 separation method Methods 0.000 description 3
URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 3
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 3
KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
206010002383 Angina Pectoris Diseases 0.000 description 2
206010008479 Chest Pain Diseases 0.000 description 2
VOPWNXZWBYDODV-UHFFFAOYSA-N Chlorodifluoromethane Chemical compound FC(F)Cl VOPWNXZWBYDODV-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
208000001871 Tachycardia Diseases 0.000 description 2
239000008365 aqueous carrier Substances 0.000 description 2
208000006673 asthma Diseases 0.000 description 2
239000000168 bronchodilator agent Substances 0.000 description 2
230000000747 cardiac effect Effects 0.000 description 2
235000019406 chloropentafluoroethane Nutrition 0.000 description 2
239000012141 concentrate Substances 0.000 description 2
239000013068 control sample Substances 0.000 description 2
238000013270 controlled release Methods 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 2
230000007423 decrease Effects 0.000 description 2
230000018044 dehydration Effects 0.000 description 2
238000006297 dehydration reaction Methods 0.000 description 2
238000009792 diffusion process Methods 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
238000009513 drug distribution Methods 0.000 description 2
239000002532 enzyme inhibitor Substances 0.000 description 2
230000007717 exclusion Effects 0.000 description 2
238000000227 grinding Methods 0.000 description 2
229960001340 histamine Drugs 0.000 description 2
238000001802 infusion Methods 0.000 description 2
230000003647 oxidation Effects 0.000 description 2
238000007254 oxidation reaction Methods 0.000 description 2
XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 2
239000006187 pill Substances 0.000 description 2
239000000843 powder Substances 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
239000000523 sample Substances 0.000 description 2
238000004513 sizing Methods 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
230000006794 tachycardia Effects 0.000 description 2
230000008685 targeting Effects 0.000 description 2
238000012360 testing method Methods 0.000 description 2
AWLILQARPMWUHA-UHFFFAOYSA-M thiopental sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC([S-])=NC1=O AWLILQARPMWUHA-UHFFFAOYSA-M 0.000 description 2
229960001295 tocopherol Drugs 0.000 description 2
239000011732 tocopherol Substances 0.000 description 2
230000001052 transient effect Effects 0.000 description 2
239000007762 w/o emulsion Substances 0.000 description 2
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
DQADPIOSMNGDGG-WCCKRBBISA-N (2r)-2-acetamido-3-sulfanylpropanoic acid;sodium Chemical compound [Na].CC(=O)N[C@@H](CS)C(O)=O DQADPIOSMNGDGG-WCCKRBBISA-N 0.000 description 1
UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
229930182837 (R)-adrenaline Natural products 0.000 description 1
SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 1
BKUKXOMYGPYFJJ-UHFFFAOYSA-N 2-ethylsulfanyl-1h-benzimidazole;hydrobromide Chemical compound Br.C1=CC=C2NC(SCC)=NC2=C1 BKUKXOMYGPYFJJ-UHFFFAOYSA-N 0.000 description 1
PBXYLMVLLSYZLN-UHFFFAOYSA-N 5beta-Ranol Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)CCO)C)C1(C)C(O)C2 PBXYLMVLLSYZLN-UHFFFAOYSA-N 0.000 description 1
VCCNKWWXYVWTLT-CYZBKYQRSA-N 7-[(2s,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)chromen-4-one Chemical compound C1=C(O)C(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(O)C=C2O[C@H]1[C@H](O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 VCCNKWWXYVWTLT-CYZBKYQRSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
229930183010 Amphotericin Natural products 0.000 description 1
QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
102000007592 Apolipoproteins Human genes 0.000 description 1
108010071619 Apolipoproteins Proteins 0.000 description 1
208000009079 Bronchial Spasm Diseases 0.000 description 1
208000014181 Bronchial disease Diseases 0.000 description 1
241000700198 Cavia Species 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
206010014561 Emphysema Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
229930186217 Glycolipid Natural products 0.000 description 1
HUYWAWARQUIQLE-UHFFFAOYSA-N Isoetharine Chemical compound CC(C)NC(CC)C(O)C1=CC=C(O)C(O)=C1 HUYWAWARQUIQLE-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
102000004882 Lipase Human genes 0.000 description 1
108090001060 Lipase Proteins 0.000 description 1
239000004367 Lipase Substances 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
206010028735 Nasal congestion Diseases 0.000 description 1
206010028741 Nasal inflammation Diseases 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
239000004365 Protease Substances 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
208000001407 Vascular Headaches Diseases 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000013566 allergen Substances 0.000 description 1
229960004784 allergens Drugs 0.000 description 1
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
229940009444 amphotericin Drugs 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000001387 anti-histamine Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
229940125715 antihistaminic agent Drugs 0.000 description 1
239000000739 antihistaminic agent Substances 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
239000011324 bead Substances 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000000035 biogenic effect Effects 0.000 description 1
230000037058 blood plasma level Effects 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
239000000919 ceramic Substances 0.000 description 1
KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
238000013461 design Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
238000011026 diafiltration Methods 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
230000010339 dilation Effects 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
150000002016 disaccharides Chemical class 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
239000013583 drug formulation Substances 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
229960005139 epinephrine Drugs 0.000 description 1
229960001903 ergotamine tartrate Drugs 0.000 description 1
210000003238 esophagus Anatomy 0.000 description 1
238000013266 extended drug release Methods 0.000 description 1
150000002190 fatty acyls Chemical group 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
239000006260 foam Substances 0.000 description 1
238000005187 foaming Methods 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
238000002309 gasification Methods 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000008103 glucose Substances 0.000 description 1
238000009532 heart rate measurement Methods 0.000 description 1
230000000887 hydrating effect Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
230000036512 infertility Effects 0.000 description 1
238000002664 inhalation therapy Methods 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
230000007794 irritation Effects 0.000 description 1
229960001268 isoetarine Drugs 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000004816 latex Substances 0.000 description 1
229920000126 latex Polymers 0.000 description 1
235000019421 lipase Nutrition 0.000 description 1
150000002634 lipophilic molecules Chemical class 0.000 description 1
239000008263 liquid aerosol Substances 0.000 description 1
238000011068 loading method Methods 0.000 description 1
210000005265 lung cell Anatomy 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
150000002772 monosaccharides Chemical class 0.000 description 1
230000004118 muscle contraction Effects 0.000 description 1
210000000754 myometrium Anatomy 0.000 description 1
XJINZNWPEQMMBV-UHFFFAOYSA-N n-methylhexan-1-amine Chemical compound CCCCCCNC XJINZNWPEQMMBV-UHFFFAOYSA-N 0.000 description 1
239000000133 nasal decongestant Substances 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
239000011236 particulate material Substances 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
229920002492 poly(sulfone) Polymers 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
239000000047 product Substances 0.000 description 1
JCRIVQIOJSSCQD-UHFFFAOYSA-N propylhexedrine Chemical compound CNC(C)CC1CCCCC1 JCRIVQIOJSSCQD-UHFFFAOYSA-N 0.000 description 1
229960000786 propylhexedrine Drugs 0.000 description 1
239000003223 protective agent Substances 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
210000003456 pulmonary alveoli Anatomy 0.000 description 1
230000004088 pulmonary circulation Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
239000003169 respiratory stimulant agent Substances 0.000 description 1
229940066293 respiratory stimulants Drugs 0.000 description 1
230000000284 resting effect Effects 0.000 description 1
238000004062 sedimentation Methods 0.000 description 1
230000009919 sequestration Effects 0.000 description 1
230000035939 shock Effects 0.000 description 1
QGMRQYFBGABWDR-UHFFFAOYSA-N sodium;5-ethyl-5-pentan-2-yl-1,3-diazinane-2,4,6-trione Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)NC1=O QGMRQYFBGABWDR-UHFFFAOYSA-N 0.000 description 1
150000003408 sphingolipids Chemical class 0.000 description 1
238000001694 spray drying Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
230000008961 swelling Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000001839 systemic circulation Effects 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
229940126585 therapeutic drug Drugs 0.000 description 1
238000009210 therapy by ultrasound Methods 0.000 description 1
239000010409 thin film Substances 0.000 description 1
231100000041 toxicology testing Toxicity 0.000 description 1
238000002627 tracheal intubation Methods 0.000 description 1
230000002792 vascular Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0005—Details of inhalators; Constructional features thereof with means for agitating the medicament
- A61M15/0006—Details of inhalators; Constructional features thereof with means for agitating the medicament using rotating means
- A61M15/0008—Details of inhalators; Constructional features thereof with means for agitating the medicament using rotating means rotating by airflow
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Pulmonology (AREA)
Epidemiology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Dispersion Chemistry (AREA)
Anesthesiology (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Otolaryngology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Plant Substances (AREA)

NO870237A 1985-05-22 1987-01-20 Fremgangsmaate og system for liposominhalering. NO870237L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US73722185A	1985-05-22	1985-05-22
PCT/US1986/001095 WO1986006959A1 (en)	1985-05-22	1986-05-21	Liposome inhalation method and system

Publications (1)

Publication Number	Publication Date
NO870237L true NO870237L (no)	1987-01-20

Family

ID=24963059

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO870237A NO870237L (no)	1985-05-22	1987-01-20	Fremgangsmaate og system for liposominhalering.

Country Status (10)

Country	Link
US (1)	US4895719A (de)
EP (1)	EP0223831B1 (de)
JP (1)	JPS63500175A (de)
AT (1)	ATE78158T1 (de)
AU (1)	AU587472B2 (de)
CA (1)	CA1257836A (de)
DE (1)	DE3686025T2 (de)
DK (1)	DK32987A (de)
NO (1)	NO870237L (de)
WO (1)	WO1986006959A1 (de)

Families Citing this family (235)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5916588A (en) *	1984-04-12	1999-06-29	The Liposome Company, Inc.	Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US6090406A (en) *	1984-04-12	2000-07-18	The Liposome Company, Inc.	Potentiation of immune responses with liposomal adjuvants
US5192528A (en) *	1985-05-22	1993-03-09	Liposome Technology, Inc.	Corticosteroid inhalation treatment method
NZ221411A (en) *	1986-08-11	1989-10-27	Innovata Biomed Ltd	Pharmaceutical compositions containing microcapsules and a surfactant
SE8603812D0 (sv) *	1986-09-12	1986-09-12	Draco Ab	Administration of liposomes to mammals
IE63869B1 (en) *	1986-11-06	1995-06-14	Res Dev Foundation	Aerosols containing liposomes and method for their preparation
US5089181A (en) *	1987-02-24	1992-02-18	Vestar, Inc.	Method of dehydrating vesicle preparations for long term storage
DE3872635T2 (de) *	1987-04-09	1992-12-17	Fisons Plc	Pentamidin enthaltende pharmazeutische zusammensetzungen.
JP2656944B2 (ja) *	1987-04-30	1997-09-24	クーパーラボラトリーズ	タンパク質性治療剤のエアロゾール化
ATE118348T1 (de) *	1987-12-04	1995-03-15	Liposome Co Inc	Liposome hoher stabilität und verfahren zur herstellung und verwendung.
FI913899A7 (fi) *	1989-02-23	1991-08-19	Rorer Int Holdings Inc	Terapeuttiset aerosoliseokset
US5174988A (en) *	1989-07-27	1992-12-29	Scientific Development & Research, Inc.	Phospholipid delivery system
AU6428890A (en) *	1989-09-12	1991-04-18	Regents Of The University Of California, The	Therapeutic peptides and proteins
US20020150539A1 (en) *	1989-12-22	2002-10-17	Unger Evan C.	Ultrasound imaging and treatment
US5773024A (en) *	1989-12-22	1998-06-30	Imarx Pharmaceutical Corp.	Container with multi-phase composition for use in diagnostic and therapeutic applications
US6551576B1 (en)	1989-12-22	2003-04-22	Bristol-Myers Squibb Medical Imaging, Inc.	Container with multi-phase composition for use in diagnostic and therapeutic applications
US5733572A (en) *	1989-12-22	1998-03-31	Imarx Pharmaceutical Corp.	Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
US5305757A (en) *	1989-12-22	1994-04-26	Unger Evan C	Gas filled liposomes and their use as ultrasonic contrast agents
US5922304A (en) *	1989-12-22	1999-07-13	Imarx Pharmaceutical Corp.	Gaseous precursor filled microspheres as magnetic resonance imaging contrast agents
US5580575A (en) *	1989-12-22	1996-12-03	Imarx Pharmaceutical Corp.	Therapeutic drug delivery systems
US5705187A (en) *	1989-12-22	1998-01-06	Imarx Pharmaceutical Corp.	Compositions of lipids and stabilizing materials
US5776429A (en) *	1989-12-22	1998-07-07	Imarx Pharmaceutical Corp.	Method of preparing gas-filled microspheres using a lyophilized lipids
US5469854A (en) *	1989-12-22	1995-11-28	Imarx Pharmaceutical Corp.	Methods of preparing gas-filled liposomes
US5585112A (en) *	1989-12-22	1996-12-17	Imarx Pharmaceutical Corp.	Method of preparing gas and gaseous precursor-filled microspheres
US5542935A (en) *	1989-12-22	1996-08-06	Imarx Pharmaceutical Corp.	Therapeutic delivery systems related applications
US6088613A (en)	1989-12-22	2000-07-11	Imarx Pharmaceutical Corp.	Method of magnetic resonance focused surgical and therapeutic ultrasound
US6146657A (en) *	1989-12-22	2000-11-14	Imarx Pharmaceutical Corp.	Gas-filled lipid spheres for use in diagnostic and therapeutic applications
US5352435A (en) *	1989-12-22	1994-10-04	Unger Evan C	Ionophore containing liposomes for ultrasound imaging
US5656211A (en) *	1989-12-22	1997-08-12	Imarx Pharmaceutical Corp.	Apparatus and method for making gas-filled vesicles of optimal size
US6001335A (en) *	1989-12-22	1999-12-14	Imarx Pharmaceutical Corp.	Contrasting agents for ultrasonic imaging and methods for preparing the same
GB9001019D0 (en) *	1990-01-17	1990-03-14	Euro Celtique Sa	Pharmaceutical aerosol
US5162361A (en) *	1990-04-10	1992-11-10	The United States Of America As Represented By The Secretary, Department Of Health And Human Services	Method of treating diseases associated with elevated levels of interleukin 1
US5370862A (en) *	1990-06-13	1994-12-06	Schwarz Pharma Ag	Pharmaceutical hydrophilic spray containing nitroglycerin for treating angina
US5258289A (en) *	1990-09-05	1993-11-02	Davis Claude G	Method for the selecting of genes encoding catalytic antibodies
US5874062A (en) *	1991-04-05	1999-02-23	Imarx Pharmaceutical Corp.	Methods of computed tomography using perfluorocarbon gaseous filled microspheres as contrast agents
US5205290A (en)	1991-04-05	1993-04-27	Unger Evan C	Low density microspheres and their use as contrast agents for computed tomography
US5993805A (en) *	1991-04-10	1999-11-30	Quadrant Healthcare (Uk) Limited	Spray-dried microparticles and their use as therapeutic vehicles
US5683714A (en) *	1991-04-19	1997-11-04	Nexstar Pharmaceuticals, Inc.	Liposomal cyclosporin pharmaceutical formulation
US5457100A (en) *	1991-12-02	1995-10-10	Daniel; David G.	Method for treatment of recurrent paroxysmal neuropsychiatric
US5639441A (en) *	1992-03-06	1997-06-17	Board Of Regents Of University Of Colorado	Methods for fine particle formation
US5814666A (en) *	1992-04-13	1998-09-29	The United States As Represented By The Department Of Health And Human Services	Encapsulated and non-encapsulated nitric oxide generators used as antimicrobial agents
US6582728B1 (en) *	1992-07-08	2003-06-24	Inhale Therapeutic Systems, Inc.	Spray drying of macromolecules to produce inhaleable dry powders
US6673335B1 (en) *	1992-07-08	2004-01-06	Nektar Therapeutics	Compositions and methods for the pulmonary delivery of aerosolized medicaments
US5350359A (en) *	1992-07-16	1994-09-27	Temple University Of The Commonwealth System Of Higher Education	Control, treatment and/or diagnosis of physiological conditions with degassed perfluorocarbon liquid
EP0679088B1 (de) *	1992-09-29	2002-07-10	Inhale Therapeutic Systems	Pulmonale abgabe von aktiven fragmenten des parathormons
WO1994017538A2 (en) *	1993-01-21	1994-08-04	Mayo Foundation For Medical Education And Research	Microparticle switching devices
US7448375B2 (en) *	1993-01-29	2008-11-11	Aradigm Corporation	Method of treating diabetes mellitus in a patient
US6024090A (en) *	1993-01-29	2000-02-15	Aradigm Corporation	Method of treating a diabetic patient by aerosolized administration of insulin lispro
US5441060A (en) *	1993-02-08	1995-08-15	Duke University	Dry powder delivery system
US5654006A (en) *	1993-02-12	1997-08-05	Mayo Foundation For Medical Education And Research	Condensed-phase microparticle composition and method
US5593661A (en) *	1993-03-29	1997-01-14	Henry; Richard A.	Lidocaine aerosol anaesthetic
AU732440B2 (en) *	1993-06-11	2001-04-26	Imarx Pharmaceutical Corp.	Novel therapeutic delivery systems
US5747445A (en) *	1993-06-24	1998-05-05	Astra Aktiebolag	Therapeutic preparation for inhalation
US6794357B1 (en)	1993-06-24	2004-09-21	Astrazeneca Ab	Compositions for inhalation
US20010003739A1 (en) *	1993-06-24	2001-06-14	Astrazeneca Ab	Systemic administration of a therapeutic preparation
US5830853A (en) *	1994-06-23	1998-11-03	Astra Aktiebolag	Systemic administration of a therapeutic preparation
IS1796B (is) *	1993-06-24	2001-12-31	Ab Astra	Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
TW402506B (en)	1993-06-24	2000-08-21	Astra Ab	Therapeutic preparation for inhalation
US6632456B1 (en)	1993-06-24	2003-10-14	Astrazeneca Ab	Compositions for inhalation
CA2163860A1 (en) *	1993-06-30	1995-01-12	Chung C. Hsu	Method for preparing liposomes
WO1995009612A1 (en) *	1993-10-07	1995-04-13	Entremed, Inc.	Encapsulated and non-encapsulated nitric oxide generators used as antimicrobial agents
US5994339A (en) *	1993-10-15	1999-11-30	University Of Alabama At Birmingham Research Foundation	Oxidant scavengers
US5747026A (en) *	1993-10-15	1998-05-05	University Of Alabama At Birmingham Research Foundation	Antioxidants
US6127356A (en)	1993-10-15	2000-10-03	Duke University	Oxidant scavengers
US7083572B2 (en) *	1993-11-30	2006-08-01	Bristol-Myers Squibb Medical Imaging, Inc.	Therapeutic delivery systems
DE4402867C1 (de) *	1994-01-31	1995-06-14	Rentschler Arzneimittel	Liposomen enthaltend darin verkapselte Proteine, Verfahren zu ihrer Herstellung sowie diese Liposomen enthaltende pharmazeutische und kosmetische Zubereitungen
US6773719B2 (en)	1994-03-04	2004-08-10	Esperion Luv Development, Inc.	Liposomal compositions, and methods of using liposomal compositions to treat dislipidemias
US6312719B1 (en) *	1994-03-04	2001-11-06	The University Of British Columbia	Liposome compositions and methods for the treatment of atherosclerosis
ATE416755T1 (de) *	1994-03-07	2008-12-15	Nektar Therapeutics	Verfahren und zusammensetzung für die pulmonale darreichung von insulin
US6102036A (en) *	1994-04-12	2000-08-15	Smoke-Stop	Breath activated inhaler
US5451569A (en) *	1994-04-19	1995-09-19	Hong Kong University Of Science And Technology R & D Corporation Limited	Pulmonary drug delivery system
MX9605717A (es) *	1994-05-18	1998-05-31	Inhale Therapeutic Syst	Metodos y composiciones para la formulacion de polvo seco de interferones.
US5736121A (en) *	1994-05-23	1998-04-07	Imarx Pharmaceutical Corp.	Stabilized homogenous suspensions as computed tomography contrast agents
US6165976A (en)	1994-06-23	2000-12-26	Astra Aktiebolag	Therapeutic preparation for inhalation
US6290991B1 (en)	1994-12-02	2001-09-18	Quandrant Holdings Cambridge Limited	Solid dose delivery vehicle and methods of making same
WO1996009053A1 (en) *	1994-09-20	1996-03-28	Duke University	Oxidoreductase activity of manganic porphyrins
US6743779B1 (en)	1994-11-29	2004-06-01	Imarx Pharmaceutical Corp.	Methods for delivering compounds into a cell
EP1283035A3 (de) *	1994-12-22	2003-03-19	AstraZeneca AB	Parathyroidhormon enthaltende therapeutische Zubereitung zur Inhalation
SE9404468D0 (sv) *	1994-12-22	1994-12-22	Astra Ab	Powder formulations
US6524557B1 (en)	1994-12-22	2003-02-25	Astrazeneca Ab	Aerosol formulations of peptides and proteins
EE9700138A (et)	1994-12-22	1997-12-15	Astra Aktiebolag	Aerosoolravimvormid
US5854202A (en) *	1995-01-24	1998-12-29	Dedhar; Shoukat	Peptide fragments of calreticulin, peptide mimetics thereof, and pharmaceutical compostions comprising same
US6518397B1 (en)	1997-07-24	2003-02-11	Shoukat Dedhar	Pharmaceuticals for modulating hormone responsiveness
US5830430A (en) *	1995-02-21	1998-11-03	Imarx Pharmaceutical Corp.	Cationic lipids and the use thereof
CA2218879A1 (en) *	1995-05-12	1996-11-14	Genentech, Inc.	Coarse spray delivery of functional biologic materials
US5997898A (en) *	1995-06-06	1999-12-07	Imarx Pharmaceutical Corp.	Stabilized compositions of fluorinated amphiphiles for methods of therapeutic delivery
US6139819A (en) *	1995-06-07	2000-10-31	Imarx Pharmaceutical Corp.	Targeted contrast agents for diagnostic and therapeutic use
US5693336A (en) *	1995-06-07	1997-12-02	Nexstar Pharmaceuticals, Inc.	Blood stable liposomal cyclosporin formulations
US6231834B1 (en)	1995-06-07	2001-05-15	Imarx Pharmaceutical Corp.	Methods for ultrasound imaging involving the use of a contrast agent and multiple images and processing of same
US6521211B1 (en) *	1995-06-07	2003-02-18	Bristol-Myers Squibb Medical Imaging, Inc.	Methods of imaging and treatment with targeted compositions
US6033645A (en) *	1996-06-19	2000-03-07	Unger; Evan C.	Methods for diagnostic imaging by regulating the administration rate of a contrast agent
US5603918A (en) *	1995-06-09	1997-02-18	Boehringer Ingelheim Pharmaceuticals, Inc.	Aerosol composition of a salt of ipratropium and a salt of albuterol
WO1997040679A1 (en)	1996-05-01	1997-11-06	Imarx Pharmaceutical Corp.	Methods for delivering compounds into a cell
US6652837B1 (en)	1996-05-24	2003-11-25	Massachusetts Institute Of Technology	Preparation of novel particles for inhalation
US20020052310A1 (en) *	1997-09-15	2002-05-02	Massachusetts Institute Of Technology The Penn State Research Foundation	Particles for inhalation having sustained release properties
GB9615350D0 (en) *	1996-07-22	1996-09-04	Resource Medical Limited	Hormone replacement therapy
GB9616237D0 (en)	1996-08-01	1996-09-11	Norton Healthcare Ltd	Aerosol formulations
US6414139B1 (en)	1996-09-03	2002-07-02	Imarx Therapeutics, Inc.	Silicon amphiphilic compounds and the use thereof
ES2289188T3 (es) *	1996-09-11	2008-02-01	Bristol-Myers Squibb Medical Imaging, Inc.	Procedimiento para la obtencion de imagenes para el diagnostico usando un agente de contraste y un vasodilatador.
US5846517A (en) *	1996-09-11	1998-12-08	Imarx Pharmaceutical Corp.	Methods for diagnostic imaging using a renal contrast agent and a vasodilator
US6056973A (en)	1996-10-11	2000-05-02	Sequus Pharmaceuticals, Inc.	Therapeutic liposome composition and method of preparation
RU2174390C2 (ru) *	1996-10-16	2001-10-10	Рисерч Дивелопмент Фаундейшн	Высокодозированные липосомные аэрозольные фармацевтические композиции
AU741439B2 (en) *	1996-12-30	2001-11-29	Battelle Memorial Institute	Formulation and method for treating neoplasms by inhalation
US6120751A (en)	1997-03-21	2000-09-19	Imarx Pharmaceutical Corp.	Charged lipids and uses for the same
US6537246B1 (en) *	1997-06-18	2003-03-25	Imarx Therapeutics, Inc.	Oxygen delivery agents and uses for the same
US6090800A (en) *	1997-05-06	2000-07-18	Imarx Pharmaceutical Corp.	Lipid soluble steroid prodrugs
US6143276A (en) *	1997-03-21	2000-11-07	Imarx Pharmaceutical Corp.	Methods for delivering bioactive agents to regions of elevated temperatures
US20050019266A1 (en) *	1997-05-06	2005-01-27	Unger Evan C.	Novel targeted compositions for diagnostic and therapeutic use
US7452551B1 (en)	2000-10-30	2008-11-18	Imarx Therapeutics, Inc.	Targeted compositions for diagnostic and therapeutic use
US20020039594A1 (en) *	1997-05-13	2002-04-04	Evan C. Unger	Solid porous matrices and methods of making and using the same
US6416740B1 (en)	1997-05-13	2002-07-09	Bristol-Myers Squibb Medical Imaging, Inc.	Acoustically active drug delivery systems
US20030035778A1 (en) *	1997-07-14	2003-02-20	Robert Platz	Methods and compositions for the dry powder formulation of interferon
US7179615B1 (en) *	1997-07-29	2007-02-20	Menzies School Of Health Research	Method of prophylaxis and treatment
US7052678B2 (en)	1997-09-15	2006-05-30	Massachusetts Institute Of Technology	Particles for inhalation having sustained release properties
US6548047B1 (en)	1997-09-15	2003-04-15	Bristol-Myers Squibb Medical Imaging, Inc.	Thermal preactivation of gaseous precursor filled compositions
AU756693B2 (en) *	1997-09-29	2003-01-23	Novartis Ag	Stabilized bioactive preparations and methods of use
WO1999023097A1 (en)	1997-11-03	1999-05-14	Duke University	Substituted porphyrins
AU1314899A (en) *	1997-11-10	1999-05-31	Sonus Pharmaceuticals, Inc.	Emulsions for aerosolization and drug delivery
US6482391B1 (en) *	1997-12-03	2002-11-19	Britannia Pharmaceuticals Limited	Medicaments for asthma treatment
US6123923A (en) *	1997-12-18	2000-09-26	Imarx Pharmaceutical Corp.	Optoacoustic contrast agents and methods for their use
US20010003580A1 (en)	1998-01-14	2001-06-14	Poh K. Hui	Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
ES2257858T3 (es)	1998-04-24	2006-08-01	Duke University	Porfirinas sustituidas.
US6956021B1 (en) *	1998-08-25	2005-10-18	Advanced Inhalation Research, Inc.	Stable spray-dried protein formulations
US6703384B2 (en) *	1998-09-23	2004-03-09	Research Development Foundation	Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
US8933032B2 (en)	1998-10-20	2015-01-13	Children's Hospital Medical Center	Surfactant protein D for the treatment of disorders associated with lung injury
EP1839648A3 (de) *	1998-11-12	2007-11-21	Transave, Inc.	Inhalationssystem
KR20010111564A (ko) *	1998-11-12	2001-12-19	프랭크 쥐. 필키윅즈	흡입 시스템
GB9912639D0 (en) *	1999-05-28	1999-07-28	Britannia Pharmaceuticals Ltd	Improvements in and relating to treatment of respiratory conditions
ATE312103T1 (de)	1999-01-25	2005-12-15	Nat Jewish Med & Res Center	Substituierte porphyrine und deren therapeutische verwendungen
US20050196345A1 (en) *	1999-02-03	2005-09-08	Max-Delbruck-Centrum Fur Molekulare Medizin	Compressed air inhaler for pulmonary application of liposomal powder aerosols and powder aerosols
HUP0105445A2 (en)	1999-02-03	2002-06-29	Fraunhofer Ges Forschung	Compressed air inhaler for pulmonary application of liposomal powder aerosols and powder aerosols suitable therefor
US6521212B1 (en) *	1999-03-18	2003-02-18	United Therapeutics Corporation	Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation
US6613352B2 (en)	1999-04-13	2003-09-02	Universite De Montreal	Low-rigidity liposomal formulation
US7258850B2 (en) *	1999-05-04	2007-08-21	Aradigm Corporation	Methods and compositions for treating erectile dysfunction
AU773385B2 (en) *	1999-05-14	2004-05-27	Esperion Luv Development, Inc.	Method of treating angina and/or anginal equivalents, and pharmaceutical compositions and kit related thereto
NZ515644A (en) *	1999-06-04	2004-12-24	Skyepharma Inc	Oil-core compositions for the sustained release of hydrophobic drugs
EP1183061B2 (de) *	1999-06-05	2012-10-17	Innovata Biomed Limited	Verabreichungsystem für medikamente
EP1210067A2 (de) *	1999-08-25	2002-06-05	Advanced Inhalation Research, Inc.	Modulation der freigabe aus trockenpulverformulierungen
US20010036481A1 (en) *	1999-08-25	2001-11-01	Advanced Inhalation Research, Inc.	Modulation of release from dry powder formulations
US6749835B1 (en)	1999-08-25	2004-06-15	Advanced Inhalation Research, Inc.	Formulation for spray-drying large porous particles
US7678364B2 (en)	1999-08-25	2010-03-16	Alkermes, Inc.	Particles for inhalation having sustained release properties
GB9920839D0 (en) *	1999-09-04	1999-11-10	Innovata Biomed Ltd	Inhaler
US6156294A (en) *	1999-11-28	2000-12-05	Scientific Development And Research, Inc.	Composition and method for treatment of otitis media
US6676930B2 (en)	1999-11-28	2004-01-13	Scientific Development And Research, Inc.	Composition and method for treatment of otitis media
AU2729101A (en) *	1999-12-21	2001-07-03	Rxkinetix, Inc.	Particulate drug-containing products and method of manufacture
US6761909B1 (en)	1999-12-21	2004-07-13	Rxkinetix, Inc.	Particulate insulin-containing products and method of manufacture
RU2263672C2 (ru) *	2000-02-11	2005-11-10	Рисерч Дивелопмент Фаундейшн	Токоферолы, токотриенолы, другие хроманы и производные по боковым цепям и их применение
US8404217B2 (en) *	2000-05-10	2013-03-26	Novartis Ag	Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
AU2001280934A1 (en) *	2000-07-28	2002-02-13	Alliance Pharmaceutical Corp.	Methods and compositions to upregulate, redirect or limit immune responses to bioactive compounds
US6514482B1 (en)	2000-09-19	2003-02-04	Advanced Inhalation Research, Inc.	Pulmonary delivery in treating disorders of the central nervous system
US6613308B2 (en) *	2000-09-19	2003-09-02	Advanced Inhalation Research, Inc.	Pulmonary delivery in treating disorders of the central nervous system
KR100743404B1 (ko)	2000-12-21	2007-07-30	넥타르 테라퓨틱스	폴리엔 항균제의 폐 전달
US20020141946A1 (en) *	2000-12-29	2002-10-03	Advanced Inhalation Research, Inc.	Particles for inhalation having rapid release properties
DE60233317D1 (de) *	2001-01-19	2009-09-24	Nat Jewish Med & Res Center	Medikament zum schutz in der radiotherapie
DE60221640T2 (de) *	2001-02-06	2008-05-21	Innovata Biomed Ltd., St. Albans	Bimodale trockenpulverzusammensetzung zur inhalation
GB0102902D0 (en) *	2001-02-06	2001-03-21	Innovata Biomed Ltd	Medicaments
US20030051728A1 (en) *	2001-06-05	2003-03-20	Lloyd Peter M.	Method and device for delivering a physiologically active compound
US7645442B2 (en)	2001-05-24	2010-01-12	Alexza Pharmaceuticals, Inc.	Rapid-heating drug delivery article and method of use
US20070122353A1 (en) *	2001-05-24	2007-05-31	Hale Ron L	Drug condensation aerosols and kits
WO2002094242A1 (en) *	2001-05-24	2002-11-28	Alexza Molecular Delivery Corporation	Delivery of rizatriptan or zolmitriptan through an inhalation route
US7090830B2 (en)	2001-05-24	2006-08-15	Alexza Pharmaceuticals, Inc.	Drug condensation aerosols and kits
JP2005503425A (ja) *	2001-05-24	2005-02-03	アレックザモレキュラーデリヴァリーコーポレイション	所定の吸入ルートによる薬剤エステルの送出
US7458374B2 (en) *	2002-05-13	2008-12-02	Alexza Pharmaceuticals, Inc.	Method and apparatus for vaporizing a compound
US7078016B2 (en) *	2001-11-21	2006-07-18	Alexza Pharmaceuticals, Inc.	Delivery of caffeine through an inhalation route
US7585493B2 (en)	2001-05-24	2009-09-08	Alexza Pharmaceuticals, Inc.	Thin-film drug delivery article and method of use
ATE415155T1 (de) *	2001-05-24	2008-12-15	Alexza Pharmaceuticals Inc	Verabreichung von alprazolam, estazolam, midazolam oder triazolam durch inhalation
US7498019B2 (en)	2001-05-24	2009-03-03	Alexza Pharmaceuticals, Inc.	Delivery of compounds for the treatment of headache through an inhalation route
WO2002094240A1 (en) *	2001-05-24	2002-11-28	Alexza Molecular Delivery Corporation	Delivery of physiologically active compounds through an inhalation route
EP1439842A4 (de) *	2001-06-01	2009-09-02	Nat Jewish Med & Res Center	Oxidantienfänger zur behandlung von diabetes oder zur verwendung bei der transplantation oder induktion von immuntoleranz
US7125568B2 (en)	2001-08-23	2006-10-24	Sung Michael T	Lipophilic drug compositions
JP2005518266A (ja) *	2001-09-28	2005-06-23	エスペリオンセラピューティクス，インコーポレイテッド	高圧でベシクルを押し出す方法および装置
WO2003041693A1 (en) *	2001-11-09	2003-05-22	Alexza Molecular Delivery Corporation	Delivery of diazepam through an inhalation route
ES2387886T3 (es) *	2001-11-13	2012-10-03	Celator Pharmaceuticals, Inc.	Composiciones que transportan lípidos con una mejor estabilidad sanguínea
US20030129250A1 (en) *	2001-11-20	2003-07-10	Advanced Inhalation Research Inc.	Particulate compositions for improving solubility of poorly soluble agents
AU2002352836B2 (en) *	2001-11-20	2005-09-29	Alkermes, Inc.	Improved particulate compositions for pulmonary delivery
GB0128148D0 (en) *	2001-11-23	2002-01-16	Innovata Biomed Ltd	Assembly
EP1463487B1 (de) *	2001-12-19	2010-05-19	Research Development Foundation	Liposomale abgabe von verbindungen auf vitamin-e-basis
US20030236301A1 (en) *	2001-12-19	2003-12-25	Bob Sanders	Liposomal delivery of vitamin E based compounds
RU2328273C2 (ru) *	2001-12-19	2008-07-10	Рисерч Дивелопмент Фаундейшн	Липосомальная доставка соединений, основанных на витамине е
JP2005530704A (ja) *	2002-03-05	2005-10-13	トランセイブ，インク．	細胞内感染を予防及び治療するための吸入システム
JP2005519129A (ja) *	2002-03-05	2005-06-30	クリーブランドステートユニバーシティー	エアロゾル薬物送達のための凝集粒子
AU2003218307B8 (en) *	2002-03-20	2006-08-31	Alkermes, Inc.	Pulmonary delivery for levodopa
DE10214983A1 (de)	2002-04-04	2004-04-08	TransMIT Gesellschaft für Technologietransfer mbH	Vernebelbare Liposomen und ihre Verwendung zur pulmonalen Applikation von Wirkstoffen
US20040009216A1 (en) *	2002-04-05	2004-01-15	Rodrigueza Wendi V.	Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease
WO2003094900A1 (en)	2002-05-13	2003-11-20	Alexza Molecular Delivery Corporation	Delivery of drug amines through an inhalation route
US20060193788A1 (en) *	2002-11-26	2006-08-31	Hale Ron L	Acute treatment of headache with phenothiazine antipsychotics
US6930137B2 (en) *	2002-05-31	2005-08-16	Fina Technology, Inc.	Method of improving blown film processing performance and physical properties
US7485721B2 (en) *	2002-06-07	2009-02-03	Duke University	Substituted porphyrins
US20040213837A1 (en) *	2002-08-05	2004-10-28	Sankaram Mantripragada	Oil-core compositions for the sustained release of hydrophobic drugs
PT1581236E (pt)	2002-10-29	2013-12-24	Insmed Inc	Libertação prolongada de anti-infecciosos
US7879351B2 (en)	2002-10-29	2011-02-01	Transave, Inc.	High delivery rates for lipid based drug formulations, and methods of treatment thereof
US7718189B2 (en)	2002-10-29	2010-05-18	Transave, Inc.	Sustained release of antiinfectives
JP2006514934A (ja) *	2002-11-26	2006-05-18	アレックザファーマシューティカルズ，インコーポレイテッド	疼痛治療用薬剤製造のためのロキサピンまたはアモキサピンの使用
MXPA05005609A (es) *	2002-11-26	2005-07-26	Alexza Pharmaceuticals Inc	Tratamiento de dolor de cabeza con antipsicoticos suministrados por inhalacion.
US20040105818A1 (en) *	2002-11-26	2004-06-03	Alexza Molecular Delivery Corporation	Diuretic aerosols and methods of making and using them
US7550133B2 (en) *	2002-11-26	2009-06-23	Alexza Pharmaceuticals, Inc.	Respiratory drug condensation aerosols and methods of making and using them
US7913688B2 (en) *	2002-11-27	2011-03-29	Alexza Pharmaceuticals, Inc.	Inhalation device for producing a drug aerosol
US20040234916A1 (en)	2003-05-21	2004-11-25	Alexza Molecular Delivery Corporation	Optically ignited or electrically ignited self-contained heating unit and drug-supply unit employing same
EP1628637A2 (de) *	2003-05-30	2006-03-01	Alza Corporation	Verfahren zur pulmonalen verabreichung eines mittels
DE602004028155D1 (de) *	2003-12-16	2010-08-26	United Therapeutics Corp	Verwendung von treprostinil zur behandlung von ischämischen läsionen
US20090124697A1 (en) *	2003-12-16	2009-05-14	United Therapeutics Corporation	Inhalation formulations of treprostinil
US7994225B2 (en) *	2004-03-17	2011-08-09	Rempex Pharmaceuticals, Inc.	Bacterial efflux pump inhibitors for the treatment of ophthalmic and otic infections
JP2008500965A (ja) *	2004-03-17	2008-01-17	エムペックス・ファーマシューティカルズ・インコーポレーテッド	細菌の排出ポンプ阻害剤の使用および投与
WO2005102429A1 (en) *	2004-04-21	2005-11-03	Innovata Biomed Limited	Inhaler
GB0409197D0 (en)	2004-04-24	2004-05-26	Innovata Biomed Ltd	Device
US7540286B2 (en) *	2004-06-03	2009-06-02	Alexza Pharmaceuticals, Inc.	Multiple dose condensation aerosol devices and methods of forming condensation aerosols
US20060051406A1 (en) *	2004-07-23	2006-03-09	Manjeet Parmar	Formulation of insoluble small molecule therapeutics in lipid-based carriers
US20100006092A1 (en) *	2004-08-12	2010-01-14	Alexza Pharmaceuticals, Inc.	Aerosol Drug Delivery Device Incorporating Percussively Activated Heat Packages
EP1781360A1 (de) *	2004-08-12	2007-05-09	Alexza Pharmaceuticals, Inc.	Aerosol-arzneiabgabevorrichtung mit perkussiv aktivierten wärmepackungen
US8337815B2 (en) *	2004-12-23	2012-12-25	Discovery Laboratories, Inc.	Pulmonary surfactant formulations
US20070031342A1 (en) *	2005-06-22	2007-02-08	Nektar Therapeutics	Sustained release microparticles for pulmonary delivery
JP5276982B2 (ja)	2005-08-26	2013-08-28	ボードオブトラスティーズオブザレランドスタンフォードジュニアユニバーシティ	オキシトシンの投与による頭痛の処置のための方法
CA2631875A1 (en) *	2005-12-06	2007-10-04	Rigel Pharmaceuticals, Inc.	Formulation of insoluble small molecule therapeutics in lipid-based carriers
EP3067047B1 (de)	2005-12-08	2022-04-20	Insmed Incorporated	Antiinfektive zusammensetzungen auf lipidbasis zur behandlung von lungeninfekten
KR100795221B1 (ko)	2006-05-19	2008-01-17	한국화학연구원	암포테리신 β를 봉입하고 표면이 헤파린으로 수식된리포솜 및 그 제조 방법
US20070286814A1 (en) *	2006-06-12	2007-12-13	Medispray Laboratories Pvt. Ltd.	Stable aerosol pharmaceutical formulations
WO2008112661A2 (en)	2007-03-09	2008-09-18	Alexza Pharmaceuticals, Inc.	Heating unit for use in a drug delivery device
WO2008137717A1 (en)	2007-05-04	2008-11-13	Transave, Inc.	Compositions of multicationic drugs for reducing interactions with polyanionic biomolecules and methods and uses thereof
US9114081B2 (en)	2007-05-07	2015-08-25	Insmed Incorporated	Methods of treating pulmonary disorders with liposomal amikacin formulations
US9333214B2 (en)	2007-05-07	2016-05-10	Insmed Incorporated	Method for treating pulmonary disorders with liposomal amikacin formulations
US9119783B2 (en)	2007-05-07	2015-09-01	Insmed Incorporated	Method of treating pulmonary disorders with liposomal amikacin formulations
CN102105146A (zh)	2008-05-23	2011-06-22	国立犹太保健医院	用于治疗与暴露于烷化物质有关的损伤的方法
US20100081956A1 (en) *	2008-09-30	2010-04-01	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	Method, composition, and system to control pH in pulmonary tissue of a subject
DE102009031274A1 (de) *	2009-06-30	2011-01-13	Justus-Liebig-Universität Giessen	Liposomen zur pulmonalen Applikation
EP2394640A1 (de)	2010-05-21	2011-12-14	MediGene AG	Verbesserte liposomale Formulierungen von lipophilen Verbindungen
PL2852391T3 (pl)	2012-05-21	2022-04-11	Insmed Incorporated	Układy do leczenia infekcji płuc
US10124066B2 (en)	2012-11-29	2018-11-13	Insmed Incorporated	Stabilized vancomycin formulations
LT3466432T (lt)	2014-05-15	2020-12-28	Insmed Incorporated	Būdai, skirti plaučių netuberkuliozinėms mikobakterinėms infekcijoms gydyti
SG11201705591PA (en)	2015-01-07	2017-08-30	Trigemina Inc	Magnesium-containing oxytocin formulations and methods of use
JP7093559B2 (ja)	2016-04-12	2022-06-30	トライジェミナ，インコーポレイテッド	マグネシウム含有オキシトシン製剤および使用の方法
US12214118B2 (en)	2018-02-02	2025-02-04	Alexza Pharmaceuticals, Inc.	Electrical condensation aerosol device
EP3773505B1 (de)	2018-03-30	2026-04-29	Insmed Incorporated	Verfahren zur kontinuierlichen herstellung von liposomalen arzneimittelprodukten
EP3784213B1 (de)	2018-04-23	2023-09-06	InspirMed Corp.	Inhalierbare liposomale zubereitung mit verzögerter freisetzung zur behandlung von lungenerkrankungen
JP7449275B2 (ja)	2018-05-02	2024-03-13	インスメッドインコーポレイテッド	リポソーム薬物製剤の製造方法
GB2626483A (en) *	2021-10-14	2024-07-24	Pacira Pharmaceuticals Inc	Multivesicular liposome formulations of dexamethasone

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3551558A (en) *	1967-08-18	1970-12-29	Eisai Co Ltd	Therapeutical aerosol composition and preparation thereof
NL7012832A (de) *	1970-08-29	1972-03-02
US4011864A (en) *	1972-08-29	1977-03-15	Paul Guichard	Respiratory apparatus
US4115567A (en) *	1973-12-27	1978-09-19	Carlo Erba S. P. A.	6-Carboxy-2-(2'-pyrazinyl)-chromones and esters thereof
SE395611B (sv) *	1975-12-12	1977-08-22	Draco Ab	Aerosolinhalationsanordning avsedd for inhalering genom ett inhaleringsmunstycke av farmakologiskt aktiva substanser
DE2750090A1 (de) *	1976-11-19	1978-06-01	Sandoz Ag	Neue verabreichungsformen fuer organische verbindungen
SE7812207L (sv) *	1977-12-01	1979-06-02	Welsh Nat School Med	Apparat, forfarande och framstellda produkter for anvendning vid administration av antihistaminer
DE3166709D1 (en) *	1980-08-04	1984-11-22	Fisons Plc	Inhalation device for administering medicaments
US4312860A (en) *	1980-10-24	1982-01-26	Regents Of The University Of California	Lung surfactant compositions
EP0084898B1 (de) *	1982-01-22	1986-09-03	FISONS plc	Liposomen und Natriumcromoglycat enthaltende Präparate und Verfahren zu ihrer Herstellung
GB8322178D0 (en) *	1983-08-17	1983-09-21	Sterwin Ag	Preparing aerosol compositions
JPH0753661B2 (ja) *	1984-03-08	1995-06-07	フアレスフアーマスーチカルリサーチエヌブイ	プロ―リポソーム組成物及びリポソームの水性分散物を作る方法
GB8423436D0 (en) *	1984-09-17	1984-10-24	Riker Laboratories Inc	Preparation of liposomes
IE58110B1 (en) *	1984-10-30	1993-07-14	Elan Corp Plc	Controlled release powder and process for its preparation
GB8522964D0 (en) *	1985-09-17	1985-10-23	Biocompatibles Ltd	Aerosol
US4752466A (en) *	1987-08-31	1988-06-21	Johnson & Johnson Products, Inc.	Thrombin aerosol
JPH04214804A (ja) *	1991-02-28	1992-08-05	Sumitomo Special Metals Co Ltd	希土類・鉄・ボロン系永久磁石用合金粉末の成型方法

1986
- 1986-05-21 JP JP61503234A patent/JPS63500175A/ja active Pending
- 1986-05-21 AU AU59564/86A patent/AU587472B2/en not_active Expired
- 1986-05-21 WO PCT/US1986/001095 patent/WO1986006959A1/en not_active Ceased
- 1986-05-21 AT AT86903857T patent/ATE78158T1/de not_active IP Right Cessation
- 1986-05-21 EP EP86903857A patent/EP0223831B1/de not_active Expired
- 1986-05-21 DE DE8686903857T patent/DE3686025T2/de not_active Expired - Lifetime
- 1986-05-22 CA CA000509783A patent/CA1257836A/en not_active Expired
1987
- 1987-01-20 NO NO870237A patent/NO870237L/no unknown
- 1987-01-21 DK DK032987A patent/DK32987A/da not_active Application Discontinuation
- 1987-03-06 US US07/022,937 patent/US4895719A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
AU5956486A (en)	1986-12-24
CA1257836A (en)	1989-07-25
JPS63500175A (ja)	1988-01-21
ATE78158T1 (de)	1992-08-15
EP0223831B1 (de)	1992-07-15
DK32987D0 (da)	1987-01-21
WO1986006959A1 (en)	1986-12-04
US4895719A (en)	1990-01-23
DE3686025D1 (de)	1992-08-20
EP0223831A1 (de)	1987-06-03
DK32987A (da)	1987-03-23
DE3686025T2 (de)	1993-01-07
AU587472B2 (en)	1989-08-17
EP0223831A4 (de)	1987-10-12

Publication	Publication Date	Title
NO870237L (no)	1987-01-20	Fremgangsmaate og system for liposominhalering.
CN101366699B (zh)	2014-04-16	用于控制释放药物活性成分的新型脂质组合物气雾剂
US5340587A (en)	1994-08-23	Liposome/bronchodilator method & System
AU693632B2 (en)	1998-07-02	Proliposome powders for inhalation
JP6357481B2 (ja)	2018-07-11	プロスタサイクリン化合物およびプロスタサイクリン化合物を使用する方法
Khan et al.	2013	Liposome-based carrier systems and devices used for pulmonary drug delivery
CA2322805C (en)	2005-09-13	Fat emulsions for inhalational administration
CA2081474A1 (en)	1991-11-09	Direct spray-dried drug/lipid powder composition
WO2015138423A1 (en)	2015-09-17	Prostacylin compositions and methods for using the same
US8652512B2 (en)	2014-02-18	Nebulized liposomes for the pulmonary application of drug compounds
JPH01500668A (ja)	1989-03-09	哺乳動物にリポソームを投与するための新規システム
AU729100B2 (en)	2001-01-25	Proliposome powders for inhalation stabilised by tocopherol
JPS61200849A (ja)	1986-09-05	リポソームの製造方法
WO2021110173A1 (en)	2021-06-10	Liposome formulation of fluticasone propionate